| Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 15.07K | $ 33.76K | $ 18.91K | $ 13.82K | $ 16.72K |
| Gross Profit | $ -25.27K | $ -24.14K | $ -43.81K | $ -14.88K | $ 7.34K |
| Operating Income | $ -145.30K | $ -85.50K | $ -185.50K | $ -135.32K | $ -69.53K |
| EBITDA | $ -107.21K | $ -40.69K | $ -140.57K | $ -109.95K | $ -69.53K |
| Net Income | $ 1.44M | $ -46.73K | $ -220.64K | $ -187.14K | $ -151.45K |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 1.91M | $ 652.00 | $ 957.00 | $ 850.00 | $ 15.79K |
| Total Assets | $ 2.33M | $ 858.87K | $ 952.93K | $ 1.05M | $ 81.45K |
| Total Debt | $ 195.38K | $ 191.36K | $ 222.17K | $ 244.53K | $ 220.54K |
| Net Debt | $ 187.43K | $ 190.71K | $ 221.21K | $ 243.68K | $ 204.75K |
| Total Liabilities | $ 412.98K | $ 385.94K | $ 433.27K | $ 360.75K | $ 285.83K |
| Stockholders' Equity | $ 1.92M | $ 472.93K | $ 519.66K | $ 685.29K | $ -204.37K |
| Cash Flow | |||||
| Free Cash Flow | $ -13.11K | $ -58.80K | $ -98.90K | $ -90.73K | $ -76.64K |
| Operating Cash Flow | $ -13.11K | $ -58.80K | $ -98.90K | $ -90.73K | $ -76.64K |
| Investing Cash Flow | $ 100.00K | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Financing Cash Flow | $ -79.59K | $ 58.50K | $ 99.01K | $ 75.79K | $ 92.43K |
Breakthrough Chemistry Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.